PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH)
(Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal
leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary
outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and
objectively confirmed venous thrombosis at any site.
Phase:
Phase 3
Details
Lead Sponsor:
McMaster University
Collaborators:
Australian and New Zealand Intensive Care Society Clinical Trials Group Canadian Critical Care Trials Group Canadian Institutes of Health Research (CIHR)